Overview

• The deal transfers Microbiome Insights’ CAP-accredited Canadian laboratory and proprietary microbial sequencing IP to Mapmygenome.
• Microbiome Insights will continue operating as a contract research organization supporting global microbiome studies.
• Mapmygenome gains deep expertise in metagenomics, transcriptomics and targeted metabolomics to enhance its scientific portfolio.
• The company will introduce combined genomics-microbiome testing services to North American clients.
• The acquisition underlines Mapmygenome’s strategy to bolster its global footprint before its planned IPO in India later this year.